| Bioactivity | Linperlisib (YY-20394) is a potent, orally bioavailable and selective inhibitor of PI3Kδ extracted from patent WO 2015055071 A1, compound 10; has an IC50 of 6.4 nM[1]. | ||||||||||||
| Invitro | Linperlisib (YY-20394) is under the study for the recurrent and/or refractory follicular lymphoma. | ||||||||||||
| Name | Linperlisib | ||||||||||||
| CAS | 1702816-75-8 | ||||||||||||
| Formula | C28H37FN6O5S | ||||||||||||
| Molar Mass | 588.69 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. WO 2015055071 A1 |
Linperlisib
CAS: 1702816-75-8 F: C28H37FN6O5S W: 588.69
Linperlisib (YY-20394) is a potent, orally bioavailable and selective inhibitor of PI3Kδ extracted from patent WO
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.